| HOME >> BIOLOGY >> TECHNOLOGY |
11.3.7 Epigenomics Enters Into an Agreement with Pronto Diagnostics 128
11.3.8 Roche Enters into a Licensing agreement with QIAGEN 128
11.3.9 OvaGene Oncology Enters into Licensing Agreement with Bergen Teknologioverforing and Medinnova 128
11.3.10 bioMerieux Signs into a Co-development Agreement with GlaxoSmithKline 129
11.3.11 IDL Biotech Enters into a Licensing Agreement with Radim 129
11.3.12 Sysmex Europe Enters Into an Agreement with Adnagen 129
11.3.13 Immunogenetics Signs an Agreement with Adnagen 130
12 Appendix 131
12.1 Definition 131
12.2 Acronyms 132
12.3 Research Methodology 133
12.4 Secondary Research 133
12.5 Primary Research 133
12.6 Models 134
12.7 Forecasts 134
12.8 Expert Panels 134
12.9 GlobalData Consulting 134
12.10 Contact Us 135
12.11 Disclaimer 135
List of Tables
Table 1: Global Cancer Incidence, Most Common Cancers, by Sex, 2008 16
Table 2: Types of Tumor Markers 18
Table 3: Tumor Markers Market, Global, Revenue ($m), 2003 – 2010 20
Table 4: Tumor Markers Market, Global, Revenue ($m), 2010 – 2017 21
Table 5: Increase in Specificity and Sensitivity, Multi-Marker Tests 23
Table 6: Cancer Incidence, by Geography, (%), 2008 24
Table 7: Tumor Markers Market, The US, Revenue ($m), 2003-2010 29
Table 8: Tumor Markers Market, The US, Revenue ($m), 2010-2017 30
Table 9: Tumor Markers Market, Canada, Revenue ($m), 2003-2010 31
Table 10: Tumor Markers Market, Canada, Revenue ($m), 2010-2017 32
Table 11: Tumor Markers Market, The UK, Revenue ($m), 2003-2010 33
Table 12: Tumor Markers Market, The UK, Revenue ($m), 2010-2017 34
Table 13: Tumor Markers Market, Germany, Revenue ($m), 2003-2010 35
Table 14: Tumor Markers Market, Germany, Revenue ($m), 2010-2017 36
Table 15: Tumor Markers
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |